SciELO - Scientific Electronic Library Online

 
vol.72 número3Urticaria Crónica Espontánea con Superposición de endotipos tipo I/IIb en un paciente con enfermedad de GravesProtocolo de retiro de Omalizumab en Urticaria crónica espontánea: Caso clínico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Revista alergia México

versión On-line ISSN 2448-9190

Resumen

VALERDI-ZEPEDA, Brenda Mariel et al. Desensitization to Acetylsalicylic Acid in patients with coronary artery disease. Rev. alerg. Méx. [online]. 2025, vol.72, n.3, pp.82-82.  Epub 08-Dic-2025. ISSN 2448-9190.  https://doi.org/10.29262/ram.v72i3.1519.

Case report:

A 77-year-old male patient with a history of facial angioedema 20 years prior after ingesting 500 mg of acetylsalicylic acid (ASA). In 2024, he underwent angioplasty with coronary stenting without ASA. He was admitted to the emergency department with chest pain. Coronary angiography confirmed acute myocardial infarction requiring stenting and repositioning. The catheterization department recommended triple therapy with clopidogrel, anticoagulant, and ASA. Due to the history of adverse reactions, a consultation was requested to assess tolerance to ASA. An oral challenge/desensitization was performed. Prior to the procedure, he presented with a peak expiratory flow (PEF) of 450 L/min, normal vital signs (VS), and a 5-point clinical score. ASA was administered every 15 minutes in progressive doses of 10 mg, 32 mg, 85 mg, and 174 mg, until reaching a cumulative dose of 301 mg. PEF, SV, and EC were monitored every 15 minutes for up to 4 hours after the start of treatment, with no changes. The following day, a loading dose of 300 mg of ASA was administered prior to coronary catheterization, followed by a maintenance dose of 100 mg/d.

Conclusion:

Various desensitization regimens exist. Khan proposes a regimen with 90-minute intervals using doses of 40.5 mg, 81 mg, 162 mg, and 325 mg. In our case, reducing the intervals to 15 minutes facilitated desensitization in a shorter time, which is useful in cardiac emergencies. Desensitization allowed tolerance to the loading dose prior to cardiac intervention and the maintenance dose without adverse reactions.

Palabras llave : Oral challenge; Desensitization; Acetylsalicylic acid.

        · resumen en Español     · texto en Español     · Español ( pdf )